HIV-1 and amyloid beta interactions at the blood-brain barrier

Project: Research project

Project Details

Description

ABSTRACT The most significant development in HIV epidemiology is the increasing age in the infected population. Among HIV-associated comorbidities that have been related to aging, neurocognitive dysfunction and vascular disorders are particularly striking. The current proposal links both conditions together by focusing on the blood-brain barrier (BBB) and neurogenesis of neural progenitor cells (NPC). HIV infected brains are characterized by increased deposition of amyloid beta (A?), and we demonstrated in the previous funding cycle that the BBB (formed primarily by the endothelium of brain capillaries) actively participates in this process. The current proposal will explore the role of the brain endothelium-derived extracellular vesicles (ECV) in A? transfer to neural progenitor cells (NPC) and their impaired neurogenesis in HIV-infected brains. The proposed research is built on the notion that enhanced accumulation of A?, toxicity of anti-retroviral therapeutics, and residual viral replication in HIV-infected brain are driving the brain pathology resulting in neurocognitive decline. The central hypothesis of the proposal is that A? carried by ECV derived from the brain endothelium enhances HIV infection of NPC and impairs their differentiation into the neuronal lineage, resulting in neurocognitive decline. Specific mechanisms evaluated in this application include the impact of A? carried by the brain endothelium-derived ECV on HIV infection and the impaired neurogenesis of NPC (Aim 1), alterations of gap junction-mediated intercellular communication between infected and non-infected NPC (Aim 2), and (Aim 3) the contribution of anti-retroviral drugs to amyloid deposition and impaired neurogenesis of NPC in HIV-infected brain. Overall, the proposal offers a unique perspective on the interactions between the BBB and A? deposits in a HIV-infected brain, resulting in impaired NPC neurogenesis. We expect that the project will provide proof-of-principle for the involvement of A? in the development of cognitive dysfunction in HIV.
StatusActive
Effective start/end date9/20/054/30/22

Funding

  • National Institute of Mental Health: $481,646.00
  • National Institute of Mental Health: $498,815.00
  • National Institute of Mental Health: $363,375.00
  • National Institute of Mental Health: $490,356.00
  • National Institute of Mental Health: $363,375.00
  • National Institute of Mental Health: $363,375.00
  • National Institute of Mental Health: $348,840.00
  • National Institute of Mental Health: $277,817.00
  • National Institute of Mental Health: $352,688.00
  • National Institute of Mental Health: $286,115.00
  • National Institute of Mental Health: $463,430.00
  • National Institute of Mental Health: $277,817.00
  • National Institute of Mental Health: $292,667.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.